Aronora is engaged in the commercial development of proprietary therapeutics. Rational design of its innovative therapeutic agents is expected to result in products that may be able to reduce the growth of life-threatening blood clots without the detrimental bleeding side effects characterizing antithrombotic drugs. Its products are intended for difficult-to-treat, severe, rapidly progressing, or catastrophic thrombotic blood clotting diseases.
Bates Medical Systems LLC (BMS) is developing innovative and cost effective new technology for the detection and diagnosis of breast cancer, one of the leading causes of death among women. BMS’s Automated Breast Ultrasound System (ABUS) provides a pre-operative, non-ionizing radiation evaluation of the breast to accurately identify tumor size and location without compression.
Captis Biotechnology, Inc. is a diagnostics company with the mission of commercializing discoveries that address major challenges in disease and pharmaceutical detection and monitoring. The technologies developed by Captis research and diagnostics are towards the treatment of chronic diseases such as cancer, cardiovascular, and Alzheimer’s.
Caring for someone who won’t get better is one of the most expensive and traumatic experiences we all will go through; Caregiven’s digital health platform guides families to the appropriate end-of-life support and services so they can spend less time overwhelmed by administrative tasks and more meaningful time with their loved-one.
Circumvent Pharmaceuticals is a drug discovery and development company focused on the high, unmet need of Batten patients.
Consano is the nation’s first 501(c)(3) crowdfunding platform for innovative medical research. Consano Honor Funds provide an easy way for individuals who are living with a chronic illness, or families who have lost a loved one to a disease, to share their stories and create a central hub for their fundraising efforts. The funds raised will then go to directly support the medical research project of that patient or family’s choice.
Cytolmage Inc. develops imaging diagnostics for drug screening and personalized detection of disease.
EndoSound is developing an after-market ultrasound imaging system for use with a conventional (optical) endoscope, enabling a GI physician to perform Endoscopic Ultrasound (EUS) in addition to conventional endoscopy with the same basic scope.
Forbie: A cancer patient care service.
Uses Artificial Intelligence (AI) and Natural Language Understanding (NLU) technology to seamlessly collect a patient’s physical, emotional and psychological data and provide real time augmented intelligence helping providers better manage cancer patients.
Gamma Therapeutics is an early stage biotechnology company developing novel medical devices for cardiovascular risk assessment, surgical therapy and hemorrhage control based upon the use of human clotting proteins.
Health Technology Innovations (HTI) is a Portland based startup company developing advanced medical image processing solutions using artificial intelligence and machine learning. Founded in 2017 by former Intel engineers, HTI is partnering with the Oregon Health and Science University’s National Cryo-EM Research Center to improve processing and analysis of large imaging datasets using cryogenic electron microscopy (cryo-EM), the Nobel Prize-winning imaging method that is revolutionizing structural biology.
Hemex Health is developing affordable, accurate tests for millions of people who are at risk for malaria and sickle cell disease and who lack access to viable diagnostics. The one minute, $1 Hemex malaria test is 10x to 20x more accurate than the current technology used in routine testing. Hemex’s portable solutions are designed to provide benefit quickly and effectively for healthcare workers and patients, whether in a modern clinic or remote corner of the world.
Inherent Targeting is developing nerve targeted fluorescent contrast agents to improve surgical outcomes. Nerve injury is a feared surgical complication affecting 50 million patients and incurring a $5 billion cost to the healthcare system annually. Currently, surgeons are entirely unassisted in nerve identification and preservation, relying solely on naked eye visualization or anatomical knowledge. Our technology provides direct highlighting of nerves during surgery in real time and is currently under clinical translation.
Izon Science is a world-leading provider of tools used for particle research in the nano-size range. Its TRPS measurement system is the most accurate, standardisable and practical method of measuring nanoparticles, while its qEV platform provides researchers an easy way of separating out target particles based on size.
Madorra is developing the first non-hormonal, non-invasive medical device to treat vaginal dryness and atrophy. Madorra’s simple, easy-to-use device will empower the millions of breast cancer survivors and post-menopausal women suffering from vaginal dryness to improve their sexual health and return to wellness.
Nelson BIO Research Center Inc (NBI) is a development and production of biological raw materials focused on in vitro diagnostic reagents.
Neuralexo is a biotechnology company focused on the discovery and development of treatments for the protection of tissues at risk of ischemic injury (i.e. brain, heart, kidney). Indications include injury associated with cardiac surgery, transplantation, traumatic brain injury and stroke.
The OmnEcoil is a novel device that utilizes the benefits of MRI for prostate cancer detection and tissue sampling in one integrated procedure for a more efficient and accurate diagnosis.
ProMedix Inc is a medical device company aiming to develop technology to simplify diagnostic home healthcare as well as ER/Critical Care. The current product under development is a platform technology that aides in the diagnostic evaluation as well as monitoring of therapeutic interventions of multiple medical conditions including trauma, dehydration and sepsis.
Refeyn produces a disruptive new generation of analytical instruments that measure the mass of individual molecules directly in solution. Mass photometry offers an easy and universal way to characterize the structure, dynamics and function of biomolecules, accelerating research and drug discovery.
Rewire Neuro offers artificial intelligence services for biomedical image analysis in clinical, veterinary and research applications. Rewire’s machine learning platform, Sightologist.ai, provides computer vision integration as a service to 3rd party devices and software for automation and standardization of biomedical image analysis. The Sightologist.ai engine also powers Rewire’s consumer-facing analysis software, called Pipsqueak AI, which is used by thousands of researchers around the world to quantify tissue samples.
RxHomeTest is an at-home health test provider that provides reliable, convenient, and confidential lab tests to anyone seeking to check, monitor, and prevent health issues.
Senju Pharmaceutical develops health care products for the ears, eyes, nose, skin and throat. For nearly three decades, Senju has developed ophthalmological products, recently diversifying into other areas that ensure the healthy functioning of our senses. Senju collaborates with international research initiatives, academic institutions and researchers, and industry specialists to unlock medical secrets that lead to pharmaceutical breakthroughs.
Sirona Dx accelerates the pace of targeted-therapy development to improve outcomes for cancer patients. Sirona is a technology-agnostic CRO that offers specialized high complexity genomics services supporting pharmaceutical companies with their drug discovery and development programs.
Sonivate Medical (SMI) develops and markets innovative ultrasound technology. The company’s technology opens new markets for ultrasound by extending its use into new classes of procedures and new clinical settings. The SonicEye, SMI’s first product, is a fingertip-mounted ultrasound probe that combines ultrasound imaging with simultaneous tactile feedback, while leaving both hands free to do work. 2012 BVC, 2013 WAC launch company winners. Sonivate received FDA clearance in February 2020 to market SonicEye Dual-Array Ultrasound System. The product is expected to begin rollout the summer of 2020.
StoneStable, Inc. has developed nano-technology to protect vaccines from spoilage and allows transportation and distribution at ambient temperature, eliminating the “cold-chain”. Every year 1.5 million children die from vaccine preventable diseases, many because they do not have access to vaccines. Moreover, up to 50% of vaccines, a $25 billion industry, are wasted due to problems with refrigerated transportation and storage. StoneStable, Inc. solves these problems. In addition StoneStable Inc’s technology enhances vaccine function allowing lower dosage.
SUTUREGARD Medical Inc. is an innovation company creating medical device solutions to solve surgical problems and improve outcomes. Our FDA registered devices manage the #1 unsolved problem in wound closure: high suture tension. High tension can damage tissue and lead to wound complications in at-risk surgical wounds. With HEMIGARD®ARS and SUTUREGARD®ISR tension reducing devices, many more wounds can be successfully closed that would have otherwise been left open to heal on their own, or required flaps or skin grafts. More at www.suturegard.com.
Developing Non-Invasive Neuromodulation Therapies for Parkinson’s Disease.
Established in 2012, Veana Therapeutics, Inc., is a privately held Oregon-based biotechnology company whose business strategy is to identify Alpha-TEA-based cancer immunotherapy technologies.
Alpha-TEA immunotherapy technologies are based on orally bioavailable anti-cancer agents that simultaneously kill tumor cells and stimulate the immune system. Alpha TEA platform products can be combined with other forms of immunotherapy to further improve anti-tumor activity.
Velanidi Technologies is a research and development company focused on creating therapeutics that bridge biology and microelectronics.
Vir brings together cutting-edge innovations with leading scientific expertise and management to take on some of the world’s most challenging infectious diseases for which solutions are non-existent or inadequate.
VBD advances diagnostic and therapeutic research from top universities and companies towards commercial products. Projects include blood based diagnostics for aneurysm and a therapeutic protein for multiple sclerosis, stroke, traumatic brain injury and methamphetamine use disorder.